Cargando…

SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response

Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18–82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6%...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsitsilonis, Ourania E., Paraskevis, Dimitrios, Lianidou, Evi, Terpos, Evangelos, Akalestos, Athanasios, Pierros, Vassilios, Kostaki, Evangelia Georgia, Kastritis, Efstathios, Moutsatsou, Paraskevi, Politou, Marianna, Scorilas, Andreas, Sphicopoulos, Thomas, Thomaidis, Nikolaos, Trougakos, Ioannis P., Tsakris, Athanassios, Voulgaris, Nikolaos, Daskalaki, Christina C., Evangelakou, Zoi, Fouki, Christina, Gianniou, Despoina D., Gumeni, Sentiljana, Kostopoulos, Ioannis V., Manola, Maria S., Orologas-Stavrou, Nikolaos, Panteli, Chrysanthi, Papanagnou, Eleni-Dimitra, Rousakis, Pantelis, Sklirou, Aimilia D., Smilkou, Stavroula, Stergiopoulou, Dimitra, Tsiodras, Sotirios, Dimopoulos, Meletios-Athanasios, Sfikakis, Petros P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998869/
https://www.ncbi.nlm.nih.gov/pubmed/33801380
http://dx.doi.org/10.3390/vaccines9030207
_version_ 1783670651683340288
author Tsitsilonis, Ourania E.
Paraskevis, Dimitrios
Lianidou, Evi
Terpos, Evangelos
Akalestos, Athanasios
Pierros, Vassilios
Kostaki, Evangelia Georgia
Kastritis, Efstathios
Moutsatsou, Paraskevi
Politou, Marianna
Scorilas, Andreas
Sphicopoulos, Thomas
Thomaidis, Nikolaos
Trougakos, Ioannis P.
Tsakris, Athanassios
Voulgaris, Nikolaos
Daskalaki, Christina C.
Evangelakou, Zoi
Fouki, Christina
Gianniou, Despoina D.
Gumeni, Sentiljana
Kostopoulos, Ioannis V.
Manola, Maria S.
Orologas-Stavrou, Nikolaos
Panteli, Chrysanthi
Papanagnou, Eleni-Dimitra
Rousakis, Pantelis
Sklirou, Aimilia D.
Smilkou, Stavroula
Stergiopoulou, Dimitra
Tsiodras, Sotirios
Dimopoulos, Meletios-Athanasios
Sfikakis, Petros P.
author_facet Tsitsilonis, Ourania E.
Paraskevis, Dimitrios
Lianidou, Evi
Terpos, Evangelos
Akalestos, Athanasios
Pierros, Vassilios
Kostaki, Evangelia Georgia
Kastritis, Efstathios
Moutsatsou, Paraskevi
Politou, Marianna
Scorilas, Andreas
Sphicopoulos, Thomas
Thomaidis, Nikolaos
Trougakos, Ioannis P.
Tsakris, Athanassios
Voulgaris, Nikolaos
Daskalaki, Christina C.
Evangelakou, Zoi
Fouki, Christina
Gianniou, Despoina D.
Gumeni, Sentiljana
Kostopoulos, Ioannis V.
Manola, Maria S.
Orologas-Stavrou, Nikolaos
Panteli, Chrysanthi
Papanagnou, Eleni-Dimitra
Rousakis, Pantelis
Sklirou, Aimilia D.
Smilkou, Stavroula
Stergiopoulou, Dimitra
Tsiodras, Sotirios
Dimopoulos, Meletios-Athanasios
Sfikakis, Petros P.
author_sort Tsitsilonis, Ourania E.
collection PubMed
description Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18–82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6% and monthly prevalence correlated with viral RNA-confirmed SARS-CoV-2 infections in Greece, in the same period. Notably, 49% of seropositive cases reported no history of SARS-CoV-2 infection-related clinical symptoms and 33% were unsuspected of their previous infection. Additionally, levels of anti-SARS-CoV-2 antibodies against the spike-protein receptor-binding domain were similar between symptomatic and asymptomatic individuals, irrespective of age and gender. Using Food and Drug Administration Emergency Use Authorization-approved assays, these results support the need for such studies on pandemic evaluation and highlight the development of robust humoral immune responses even among asymptomatic individuals. The high percentage of unsuspected/asymptomatic active cases, which may contribute to community transmission for more days than that of cases who are aware and self-isolate, underscores the necessity of measures across the population for the efficient control of the pandemic.
format Online
Article
Text
id pubmed-7998869
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79988692021-03-28 SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response Tsitsilonis, Ourania E. Paraskevis, Dimitrios Lianidou, Evi Terpos, Evangelos Akalestos, Athanasios Pierros, Vassilios Kostaki, Evangelia Georgia Kastritis, Efstathios Moutsatsou, Paraskevi Politou, Marianna Scorilas, Andreas Sphicopoulos, Thomas Thomaidis, Nikolaos Trougakos, Ioannis P. Tsakris, Athanassios Voulgaris, Nikolaos Daskalaki, Christina C. Evangelakou, Zoi Fouki, Christina Gianniou, Despoina D. Gumeni, Sentiljana Kostopoulos, Ioannis V. Manola, Maria S. Orologas-Stavrou, Nikolaos Panteli, Chrysanthi Papanagnou, Eleni-Dimitra Rousakis, Pantelis Sklirou, Aimilia D. Smilkou, Stavroula Stergiopoulou, Dimitra Tsiodras, Sotirios Dimopoulos, Meletios-Athanasios Sfikakis, Petros P. Vaccines (Basel) Article Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18–82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6% and monthly prevalence correlated with viral RNA-confirmed SARS-CoV-2 infections in Greece, in the same period. Notably, 49% of seropositive cases reported no history of SARS-CoV-2 infection-related clinical symptoms and 33% were unsuspected of their previous infection. Additionally, levels of anti-SARS-CoV-2 antibodies against the spike-protein receptor-binding domain were similar between symptomatic and asymptomatic individuals, irrespective of age and gender. Using Food and Drug Administration Emergency Use Authorization-approved assays, these results support the need for such studies on pandemic evaluation and highlight the development of robust humoral immune responses even among asymptomatic individuals. The high percentage of unsuspected/asymptomatic active cases, which may contribute to community transmission for more days than that of cases who are aware and self-isolate, underscores the necessity of measures across the population for the efficient control of the pandemic. MDPI 2021-03-02 /pmc/articles/PMC7998869/ /pubmed/33801380 http://dx.doi.org/10.3390/vaccines9030207 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Tsitsilonis, Ourania E.
Paraskevis, Dimitrios
Lianidou, Evi
Terpos, Evangelos
Akalestos, Athanasios
Pierros, Vassilios
Kostaki, Evangelia Georgia
Kastritis, Efstathios
Moutsatsou, Paraskevi
Politou, Marianna
Scorilas, Andreas
Sphicopoulos, Thomas
Thomaidis, Nikolaos
Trougakos, Ioannis P.
Tsakris, Athanassios
Voulgaris, Nikolaos
Daskalaki, Christina C.
Evangelakou, Zoi
Fouki, Christina
Gianniou, Despoina D.
Gumeni, Sentiljana
Kostopoulos, Ioannis V.
Manola, Maria S.
Orologas-Stavrou, Nikolaos
Panteli, Chrysanthi
Papanagnou, Eleni-Dimitra
Rousakis, Pantelis
Sklirou, Aimilia D.
Smilkou, Stavroula
Stergiopoulou, Dimitra
Tsiodras, Sotirios
Dimopoulos, Meletios-Athanasios
Sfikakis, Petros P.
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
title SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
title_full SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
title_fullStr SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
title_full_unstemmed SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
title_short SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
title_sort sars-cov-2 infection is asymptomatic in nearly half of adults with robust anti-spike protein receptor-binding domain antibody response
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998869/
https://www.ncbi.nlm.nih.gov/pubmed/33801380
http://dx.doi.org/10.3390/vaccines9030207
work_keys_str_mv AT tsitsilonisouraniae sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT paraskevisdimitrios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT lianidouevi sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT terposevangelos sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT akalestosathanasios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT pierrosvassilios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT kostakievangeliageorgia sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT kastritisefstathios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT moutsatsouparaskevi sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT politoumarianna sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT scorilasandreas sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT sphicopoulosthomas sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT thomaidisnikolaos sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT trougakosioannisp sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT tsakrisathanassios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT voulgarisnikolaos sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT daskalakichristinac sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT evangelakouzoi sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT foukichristina sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT giannioudespoinad sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT gumenisentiljana sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT kostopoulosioannisv sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT manolamarias sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT orologasstavrounikolaos sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT pantelichrysanthi sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT papanagnouelenidimitra sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT rousakispantelis sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT sklirouaimiliad sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT smilkoustavroula sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT stergiopouloudimitra sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT tsiodrassotirios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT dimopoulosmeletiosathanasios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse
AT sfikakispetrosp sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse